Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) plunged over 3% on Friday. The drop in stock price came after investment analysts at The Goldman Sachs Group issued a research report, giving the biotech company a “sell” rating.
The analysts at Goldman Sachs have set a new price objective of $1.25 for the stock, which is down from their previous target of $3.00. If the Goldman Sachs Group’s target price is reached, it would mean a potential downside of 25.82% from the stock’s previous closing price.
This recent report from Goldman Sachs is not the only one signaling a potential concern. Other research firms have also released reports on Ginkgo Bioworks. Raymond James reduced their price objective from $6.00 to $5.00 but maintained an “outperform” rating for the company back in March. William Blair downgraded Ginkgo Bioworks from an “outperform” rating to a “market perform” rating in May.
BTIG Research also adjusted its target price for Ginkgo Bioworks, lowering it from $4.00 to $3.00 in March.
Overall, out of the six analysts who have assessed the stock, one has given it a “sell” rating. Two analysts have provided a “hold” rating, while three analysts have assigned a “buy” rating. According to MarketBeat, the consensus rating for Ginkgo Bioworks is currently “Hold,” with an average target price of $4.10.
Zabih Ullah is a seasoned finance writer with more than ten years of experience. He is highly skilled at analyzing market trends, decoding economic data, and providing insightful commentary on various financial topics. Driven by his curiosity, Zabih stays updated with the latest developments in the finance industry, ensuring that his readers receive timely and relevant news and analysis.
